BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection.

Autor: Clarke CA; GRAIL LLC, Menlo Park, California, USA., Lang K; Guardant Health, Redwood City, California, USA., Putcha G; Freenome, South San Francisco, California, USA., Beer JP; Novartis, Cambridge, Massachusetts, USA., Champagne M; Illumina, San Diego, California, USA., Ferris A; Lungevity Foundation, Bethesda, Maryland, USA., Godsey JH; Quest Diagnostics, Irvine, California, USA., Grossman RL; Open Commons Consortium, Chicago, Illinois, USA., Hoyos JM; Prevent Cancer Foundation, Alexandria, Virginia, USA., Johann DJ; University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Krunic N; Novartis, Cambridge, Massachusetts, USA., Kuhn P; University of Southern California, Los Angeles, California, USA., Lee JSH; University of Southern California, Los Angeles, California, USA., Maddala T; Delfi Diagnostics, Palo Alto, California, USA., Mata M; Pfizer, San Diego, California, USA., McDole J; Bio-Rad Laboratories Inc, Digital Biology Group, Pleasanton, California, USA., Perez O; AstraZeneca, Gaithersburg, Maryland, USA., Scher H; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Stewart MD; Friends of Cancer Research, Washington, DC, USA., Bhan SS; EXACT Sciences, Madison, Wisconsin, USA., Zhang Q; GlaxoSmithKline, Collegeville, Pennsylvania, USA., Leiman LC; BLOODPAC, Chicago, Illinois, USA.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2023 Jan; Vol. 16 (1), pp. 5-9. Date of Electronic Publication: 2022 Oct 17.